Renalytix (RENXF) Financial Statements
Renalytix Financial Overview
Renalytix's market cap is currently $48.95M. The company's EPS TTM is $-0.02; its P/E ratio is -3.44; Renalytix is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 25 | Sep 24 | Jun 23 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 3.00M | $ 2.29M | $ 3.40M | $ 2.97M | $ 1.49M |
| Gross Profit | $ 1.20M | $ 156.00K | $ 701.00K | $ 874.00K | $ 633.00K |
| Operating Income | $ -17.20M | $ -29.61M | $ -42.35M | $ -53.18M | $ -31.92M |
| EBITDA | $ -21.30M | $ -28.52M | $ -41.71M | $ -52.69M | $ -30.79M |
| Net Income | $ -20.40M | $ -33.46M | $ -45.61M | $ -45.28M | $ -34.73M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.70M | $ 5.40M | $ 24.68M | $ 41.33M | $ 74.45M |
| Total Assets | $ 6.10M | $ 7.97M | $ 30.63M | $ 50.06M | $ 102.58M |
| Total Debt | $ 8.30M | $ 8.54M | $ 12.15M | $ 12.34M | $ 352.00K |
| Net Debt | $ 4.70M | $ 3.85M | $ -12.53M | $ -28.99M | $ -64.81M |
| Total Liabilities | $ 13.10M | $ 15.83M | $ 23.66M | $ 19.46M | $ 7.48M |
| Stockholders' Equity | $ -7.00M | $ -7.85M | $ 6.97M | $ 30.61M | $ 71.46M |
| Cash Flow | |||||
| Free Cash Flow | $ -17.90M | $ -30.11M | $ -32.67M | $ -46.44M | $ -26.26M |
| Operating Cash Flow | $ -17.90M | $ -30.11M | $ -34.09M | $ -45.74M | $ -24.63M |
| Investing Cash Flow | $ 0.00 | $ -4.00K | $ 0.00 | $ -694.00K | $ -741.00K |
| Financing Cash Flow | $ 16.00M | $ 10.25M | $ 16.39M | $ 25.52M | $ 77.24M |
Currency in USD